11844 Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices 

Goal 1: Enhance discovery and 

advance HIV science through 

fundamental research. 

Description: Fundamental research 

seeks to expand understanding of the 

biological, physiological, interpersonal, 

and social-structural mechanisms of 

HIV—i.e., how it operates as a virus and 

as an infectious disease pandemic—at 

the molecular, cellular, individual, 

community, and population level. This 

understanding provides the foundation 

for the development of safe, effective, 

and scalable tools to prevent, treat, and 

ultimately cure HIV infection, as well as 

reduce the risk and impact of comorbid 

conditions and co-occurring infections. 

Fundamental research includes 

theoretical, pre-clinical, and 

methodological research across 

scientific disciplines. 

Goal 2: Advance the development and 

assessment of novel interventions for 

HIV prevention, treatment, and cure. 

Description: Knowledge gleaned from 

fundamental, pre-clinical, and 

translational research to inform clinical 

trials and other intervention studies to 

test the most promising products, tools, 

or strategies for HIV prevention, 

treatment, and cure and management of 

its complications. Rigorous randomized 

control trials, observational studies, and 

other methodologies assess biological, 

behavioral, and social outcomes of 

novel interventions, as well as their 

feasibility, acceptability, effectiveness, 

and scalability in differing populations 

and across the lifespan. 

Goal 3: Optimize public health impact 

of HIV discoveries through translation, 

dissemination, and implementation of 

research findings. 

Description: As HIV prevention, 

treatment, and cure interventions are 

shown to be efficacious, their findings 

must be translated to inform practice 

and to connect with communities and 

the general public in order to maximize 

their public health impact. 

Implementation research can identify 

how best to facilitate effective 

adaptation, uptake, integration, and 

scale-up of evidence-based HIV 

interventions. Information-sharing 

through community partnerships, 

research collaborations, and 

dissemination activities can amplify the 

impact of research and promote health 

equity. 

Goal 4: Build research workforce and 

infrastructure capacity to enhance 

sustainability of HIV scientific 

discovery. 

Description: Continued progress in 

HIV science and its application requires 

robust support for research tools, 

computational resources, 

instrumentation, data and physical 

infrastructure, and workforce 

development, particularly in 

institutions that serve underrepresented 

or high HIV burden populations or that 

historically have been underfunded in 

the United States and globally. Such 

enhanced capacity-strengthening efforts 

will promote diversity and inclusion in 

the HIV research workforce. 

Respondents are also invited to share 

comments on the new framework. 

Responses to this RFI Notice are 

voluntary. The submitted information 

will be reviewed by NIH staff and may 

be made available to the public. 

Submitted information will not be 

considered confidential. This request is 

for information and planning purposes 

and should not be construed as a 

solicitation or as an obligation of the 

federal government or the NIH. No 

awards will be made based on responses 

to this Request for Information. The 

information submitted will be analyzed 

and may be used in reports or 

presentations. Those who respond are 

advised that the NIH is under no 

obligation to acknowledge receipt of 

your comments or provide comments on 

your submission. No proprietary, 

classified, confidential and/or sensitive 

information should be included in your 

response. The NIH and the government 

reserve the right to use any nonproprietary technical information in any 

future solicitation(s). 

Dated: February 5, 2024. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2024–03122 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Muscular Dystrophy 

Coordinating Committee (MDCC). 

The meeting will be held as a virtual 

meeting and will be open to the public 

as indicated below. Individuals who 

plan to view the virtual meeting and 

need special assistance or other 

reasonable accommodations to view the 

meeting, should notify the Contact 

Person listed below in advance of the 

meeting. The meeting can be accessed 

from the NIH Videocast at the following 

link: https://videocast.nih.gov/. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: March 18, 2024. 

Time: 12:00 p.m. to 4:00 p.m. ET. 

Agenda: The purpose of this meeting is to 

bring together committee members, 

representing government agencies, patient 

advocacy groups, other voluntary health 

organizations, and patients and their families 

to update one another on progress relevant to 

the Action Plan for the Muscular Dystrophies 

and to coordinate activities and discuss gaps 

and opportunities leading to better 

understanding of the muscular dystrophies, 

advances in treatments, and improvements in 

patients’ and their families’ lives. The agenda 

for this meeting will be available on the 

MDCC website: https://www.mdcc.nih.gov/. 

Registration: To register, please go to: 

https://roseliassociates.zoomgov.com/ 

meeting/register/vJItc-6hrTsuHDKRDbVsTHLsMoFRuqyoRw#/registration. 

Webcast Live: https://videocast.nih.gov/. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Glen Nuckolls, Ph.D., 

Program Director, National Institute of 

Neurological, Disorders and Stroke (NINDS), 

NIH, 6001 Executive Blvd., Bethesda, MD 

20892, 301–496–5876, MDCC@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Anyone from the public can attend the 

meeting virtually via the NIH Videocasting 

website (https://videocast.nih.gov). Please 

continue checking these websites, in addition 

to the committee website listed below, for the 

most up to date guidance as the meeting date 

approaches. 

More information can be found on the 

Muscular Dystrophy Coordinating Committee 

website: https://mdcc.nih.gov/. 

Dated: February 9, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–03106 Filed 2–14–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 


khammond on DSKJM1Z7X2PROD with NOTICES